Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Research Report 2022

CIPN is a common adverse effect of several cancer therapies including taxanes and platinum drugs. Symptoms include decreased sensation and tingling of the hands and feet, severe pain, numbness and muscle weakness, all of which can occur during cancer treatment, and frequently persist after chemotherapy has ended.

There are no approved therapies to combat the debilitating symptoms of CIPN now. Current alternatives include Palliative care using antidepressants, antiepileptic drugs, or opioids, all of which have well known adverse side effects.
Due to the COVID-19 pandemic, the global Chemotherapy Induced Peripheral Neuropathy Treatment market size is estimated to be worth US$ 1675.1 million in 2021 and is forecast to a readjusted size of US$ 2599.2 million by 2028 with a CAGR of 6.4% during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Chemotherapy Induced Peripheral Neuropathy Treatment market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Chemotherapy Induced Peripheral Neuropathy Treatment landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
Americas is the largest market with about 47% market share. Europe is follower, accounting for about 27% market share.
The key players are Aptinyx Inc, Asahi Kasei Pharma Corp, Regenacy Pharmaceuticals, MAKScientific LLC, Metys Pharmaceuticals AG, Nemus Bioscience Inc, PledPharma, Sova Pharmaceuticals Inc, DermaXon LLC, Kineta Inc, Krenitsky Pharmaceuticals Inc, PeriphaGen, Apexian Pharma, WinSanTor etc.
This report focuses on Chemotherapy Induced Peripheral Neuropathy Treatment volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Chemotherapy Induced Peripheral Neuropathy Treatment market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe and Japan, etc.
Global Chemotherapy Induced Peripheral Neuropathy Treatment Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Calcium Channel α2-delta Ligands
Antidepressants
Opioids
Others
Segment by Application
Platinum Agents
Taxanes
Vinca Alkaloids
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
Aptinyx Inc
Asahi Kasei Pharma Corp
Regenacy Pharmaceuticals
MAKScientific LLC
Metys Pharmaceuticals AG
Nemus Bioscience Inc
PledPharma
Sova Pharmaceuticals Inc
DermaXon LLC
Kineta Inc
Krenitsky Pharmaceuticals Inc
PeriphaGen
Apexian Pharma
WinSanTor

Frequently Asked Questions